<DOC>
	<DOC>NCT01344863</DOC>
	<brief_summary>This randomized, open-label, parallel, 2-arm, multicenter study will compare the administration of Herceptin (trastuzumab) with a single-use injection device versus a handheld syringe in healthy male volunteers. The volunteers will receive a single dose of 600 mg Herceptin. The anticipated time of the study is 21 weeks.</brief_summary>
	<brief_title>A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Healthy male patients, 18 to 45 years of age, inclusive No history of hypersensitivity or allergic reactions following drug administration No history of clinically significant or clinically relevant cardiac condition No history of previous anticancer treatment Body mass index (BMI) between 1832 kg/m2, inclusive Positive test result for drugs of abuse Positive test result for hepatitis B, hepatitis C, or HIV 1 or 2 Systolic blood pressure greater than 140 mmHG or less than 90 mmHG, or diastolic blood pressure greater than 90 mmHG or less than 50 mmHG Clinically significant abnormal laboratory values</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>